Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Ecological Fallacy, Nonspecific Outcomes, and the Attribution of Disproportionate Vaccine Benefits.

De Serres G, Skowronski DM.

Clin Infect Dis. 2018 May 17;66(11):1817-1818. doi: 10.1093/cid/ciy014. No abstract available.

2.

Role of egg-adaptation mutations in low influenza A(H3N2) vaccine effectiveness during the 2012-13 season.

Skowronski DM, De Serres G.

Clin Infect Dis. 2018 Apr 24. doi: 10.1093/cid/ciy350. [Epub ahead of print] No abstract available.

PMID:
29688295
3.

Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018.

Skowronski DM, Chambers C, De Serres G, Dickinson JA, Winter AL, Hickman R, Chan T, Jassem AN, Drews SJ, Charest H, Gubbay JB, Bastien N, Li Y, Krajden M.

Euro Surveill. 2018 Feb;23(5). doi: 10.2807/1560-7917.ES.2018.23.5.18-00035.

4.

Selection Bias in the Assessment of Frailty and Its Role in Influenza Vaccine Effectiveness Evaluation Among Elderly Adults.

Skowronski DM, Chambers C, De Serres G.

J Infect Dis. 2017 Dec 27;217(1):168. doi: 10.1093/infdis/jix548. No abstract available.

PMID:
29045721
5.

Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada.

Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, Gubbay JB, Drews SJ, Martineau C, Charest H, Krajden M, Bastien N, Li Y.

J Infect Dis. 2017 Dec 19;216(12):1487-1500. doi: 10.1093/infdis/jix526.

6.

Prevalence of risk factors for acquiring measles during the 2011 outbreak in Quebec and impact of the province-wide school-based vaccination campaign on population immunity.

Billard MN, De Serres G, Gariépy MC, Boulianne N, Toth E, Landry M, Skowronski DM.

PLoS One. 2017 Oct 11;12(10):e0186070. doi: 10.1371/journal.pone.0186070. eCollection 2017.

7.

Age-Related Differences in Influenza B Infection by Lineage in a Community-Based Sentinel System, 2010-2011 to 2015-2016, Canada.

Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, Gubbay JB, Fonseca K, Drews SJ, Charest H, Martineau C, Krajden M, Petric M, Bastien N, Li Y.

J Infect Dis. 2017 Sep 15;216(6):697-702. doi: 10.1093/infdis/jix393.

8.

Reply to Chung et al.

Skowronski DM, Chambers C, De Serres G.

J Infect Dis. 2017 Jul 15;216(2):285-287. doi: 10.1093/infdis/jix287. No abstract available.

PMID:
28633301
9.

Reduced antibody response to infant measles vaccination: effects based on type and timing of the first vaccine dose persist after the second dose.

Carazo Perez S, De Serres G, Bureau A, Skowronski DM.

Clin Infect Dis. 2017 Jun 8. doi: 10.1093/cid/cix510. [Epub ahead of print]

PMID:
28595358
10.

Repeated annual influenza vaccination and vaccine effectiveness: review of evidence.

Belongia EA, Skowronski DM, McLean HQ, Chambers C, Sundaram ME, De Serres G.

Expert Rev Vaccines. 2017 Jul;16(7):1-14. doi: 10.1080/14760584.2017.1334554. Epub 2017 Jun 9. Review. Erratum in: Expert Rev Vaccines. 2017 Aug;16(8):865-866.

PMID:
28562111
11.

Pooling and the Potential Dilution of Repeat Influenza Vaccination Effects.

Skowronski DM, Chambers C.

Clin Infect Dis. 2017 Jul 15;65(2):353-355. doi: 10.1093/cid/cix375. No abstract available.

PMID:
28430894
12.

RE: "DETECTABLE RISKS IN STUDIES OF THE FETAL BENEFITS OF MATERNAL INFLUENZA VACCINATION".

De Serres G, Skowronski DM.

Am J Epidemiol. 2017 May 1;185(9):860-861. doi: 10.1093/aje/kww202. No abstract available.

PMID:
28369245
13.

Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017.

Skowronski DM, Chambers C, Sabaiduc S, Dickinson JA, Winter AL, De Serres G, Drews SJ, Jassem A, Gubbay JB, Charest H, Balshaw R, Bastien N, Li Y, Krajden M.

Euro Surveill. 2017 Feb 9;22(6). pii: 30460. doi: 10.2807/1560-7917.ES.2017.22.6.30460.

14.

Serial Vaccination and the Antigenic Distance Hypothesis: Effects on Influenza Vaccine Effectiveness During A(H3N2) Epidemics in Canada, 2010-2011 to 2014-2015.

Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, Gubbay JB, Fonseca K, Drews SJ, Charest H, Martineau C, Krajden M, Petric M, Bastien N, Li Y, Smith DJ.

J Infect Dis. 2017 Apr 1;215(7):1059-1099. doi: 10.1093/infdis/jix074.

15.

Influenza Vaccination of Healthcare Workers: Critical Analysis of the Evidence for Patient Benefit Underpinning Policies of Enforcement.

De Serres G, Skowronski DM, Ward BJ, Gardam M, Lemieux C, Yassi A, Patrick DM, Krajden M, Loeb M, Collignon P, Carrat F.

PLoS One. 2017 Jan 27;12(1):e0163586. doi: 10.1371/journal.pone.0163586. eCollection 2017.

16.

Clinical Approach Used in Medical Consultations for Allergic-Like Events Following Immunization: Case Series Report in Relation to Practice Guidelines.

Zafack JG, De Serres G, Rouleau I, Gariépy MC, Gagnon R, Drolet JP, Skowronski DM.

J Allergy Clin Immunol Pract. 2017 May - Jun;5(3):718-727.e1. doi: 10.1016/j.jaip.2016.09.048. Epub 2016 Nov 30.

PMID:
27914816
17.

Repeat Influenza Vaccination and High-Dose Efficacy.

Skowronski DM, Chambers C, Gilca R, De Serres G.

Clin Infect Dis. 2016 Nov 1;63(9):1265-1266. Epub 2016 Aug 9. No abstract available.

PMID:
27506686
18.

A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season.

Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, Krajden M, Gubbay JB, Drews SJ, Martineau C, Eshaghi A, Kwindt TL, Bastien N, Li Y.

Clin Infect Dis. 2016 Jul 1;63(1):21-32. doi: 10.1093/cid/ciw176. Epub 2016 Mar 29.

19.

Interim estimates of 2015/16 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, February 2016.

Chambers C, Skowronski DM, Sabaiduc S, Winter AL, Dickinson JA, De Serres G, Gubbay JB, Drews SJ, Martineau C, Eshaghi A, Krajden M, Bastien N, Li Y.

Euro Surveill. 2016;21(11):30168. doi: 10.2807/1560-7917.ES.2016.21.11.30168.

20.

Mutations acquired during cell culture isolation may affect antigenic characterisation of influenza A(H3N2) clade 3C.2a viruses.

Skowronski DM, Sabaiduc S, Chambers C, Eshaghi A, Gubbay JB, Krajden M, Drews SJ, Martineau C, De Serres G, Dickinson JA, Winter AL, Bastien N, Li Y.

Euro Surveill. 2016;21(3):30112. doi: 10.2807/1560-7917.ES.2016.21.3.30112.

21.

Systematic community- and hospital-based surveillance for enterovirus-D68 in three Canadian provinces, August to December 2014.

Skowronski DM, Chambers C, Sabaiduc S, Murti M, Gustafson R, Pollock S, Hoyano D, Rempel S, Allison S, De Serres G, Dickinson JA, Tellier R, Fonseca K, Drews SJ, Martineau C, Reyes-Domingo F, Wong T, Tang P, Krajden M.

Euro Surveill. 2015;20(43). doi: 10.2807/1560-7917.ES.2015.20.43.30047.

22.

Avian Influenza A(H7N9) Virus Infection in 2 Travelers Returning from China to Canada, January 2015.

Skowronski DM, Chambers C, Gustafson R, Purych DB, Tang P, Bastien N, Krajden M, Li Y.

Emerg Infect Dis. 2016 Jan;22(1):71-4. doi: 10.3201/eid2201.151330.

23.

Detection of influenza A(H3N2) clade 3C.2a viruses in patients with suspected mumps in British Columbia, Canada, during the 2014/15 influenza season.

Chambers C, Skowronski DM, Sabaiduc S, Murti M, Gustafson R, Pollock S, Hoyano D, Allison S, Krajden M.

Euro Surveill. 2015;20(36). doi: 10.2807/1560-7917.ES.2015.20.36.30015. No abstract available.

24.

Paresthesia and sensory disturbances associated with 2009 pandemic vaccine receipt: Clinical features and risk factors.

De Serres G, Rouleau I, Skowronski DM, Ouakki M, Lacroix K, Bédard F, Toth E, Landry M, Dupré N.

Vaccine. 2015 Aug 26;33(36):4464-71. doi: 10.1016/j.vaccine.2015.07.028. Epub 2015 Jul 22.

25.

Mid-Season Estimates of Influenza Vaccine Effectiveness against Influenza A(H3N2) Hospitalization in the Elderly in Quebec, Canada, January 2015.

Gilca R, Skowronski DM, Douville-Fradet M, Amini R, Boulianne N, Rouleau I, Martineau C, Charest H, De Serres G.

PLoS One. 2015 Jul 22;10(7):e0132195. doi: 10.1371/journal.pone.0132195. eCollection 2015.

26.
27.

Integrated Sentinel Surveillance Linking Genetic, Antigenic, and Epidemiologic Monitoring of Influenza Vaccine-Virus Relatedness and Effectiveness During the 2013-2014 Influenza Season.

Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, Gubbay J, Fonseca K, Charest H, Krajden M, Petric M, Mahmud SM, Van Caeseele P, Bastien N, Eshaghi A, Li Y.

J Infect Dis. 2015 Sep 1;212(5):726-39. doi: 10.1093/infdis/jiv177. Epub 2015 Mar 17.

PMID:
25784728
28.

Other respiratory viruses are important contributors to adult respiratory hospitalizations and mortality even during peak weeks of the influenza season.

Gilca R, Amini R, Douville-Fradet M, Charest H, Dubuque J, Boulianne N, Skowronski DM, De Serres G.

Open Forum Infect Dis. 2014 Sep 22;1(2):ofu086. doi: 10.1093/ofid/ofu086. eCollection 2014 Sep.

29.

Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015.

Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Dickinson JA, Winter AL, Drews SJ, Fonseca K, Charest H, Gubbay JB, Petric M, Krajden M, Kwindt TL, Martineau C, Eshaghi A, Bastien N, Li Y.

Euro Surveill. 2015 Jan 29;20(4). pii: 21022. No abstract available.

30.

Case series of rash associated with influenza B in school children.

Skowronski DM, Chambers C, Osei W, Walker J, Petric M, Naus M, Li Y, Krajden M.

Influenza Other Respir Viruses. 2015 Jan;9(1):32-7. doi: 10.1111/irv.12296. Epub 2014 Nov 10.

31.

Pre- and postpandemic estimates of 2009 pandemic influenza A(H1N1) seroprotection to inform surveillance-based incidence, by age, during the 2013-2014 epidemic in Canada.

Skowronski DM, Chambers C, Sabaiduc S, Janjua NZ, Li G, Petric M, Krajden M, Purych D, Li Y, De Serres G.

J Infect Dis. 2015 Jan 1;211(1):109-14. doi: 10.1093/infdis/jiu366. Epub 2014 Jun 27.

PMID:
24973459
32.

Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada.

Rouleau I, De Serres G, Skowronski DM, Drolet JP, Lemire C, Toth E, Landry M.

Vaccine. 2014 Jun 12;32(28):3480-7. doi: 10.1016/j.vaccine.2014.04.059. Epub 2014 Apr 29.

PMID:
24793951
33.

Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses.

Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, Fonseca K, Winter AL, Gubbay JB, Krajden M, Petric M, Charest H, Bastien N, Kwindt TL, Mahmud SM, Van Caeseele P, Li Y.

PLoS One. 2014 Mar 25;9(3):e92153. doi: 10.1371/journal.pone.0092153. eCollection 2014.

34.

Interim estimates of 2013/14 vaccine effectiveness against influenza A(H1N1)pdm09 from Canada s sentinel surveillance network, January 2014.

Skowronski D, Chambers C, Sabaiduc S, De Serres G, Dickinson J, Winter A, Fonseca K, Gubbay J, Charest H, Petric M, Krajden M, Mahmud S, Van Caeseele P, Kwindt T, Eshaghi A, Bastien N, Li Y.

Euro Surveill. 2014 Feb 6;19(5). pii: 20690. Erratum in: Euro Surveill. 2014;19(6):20698.

35.

Pertussis Surveillance Trends in British Columbia, Canada, over a 20-year Period: 1993-2013.

Chambers C, Skowronski DM, Hoang L, Li HG, Fritz CE, Gustafson R, Murti M, Reid A, Parker R, Bowering D.

Can Commun Dis Rep. 2014 Feb 7;40(3):31-41. eCollection 2014 Feb 7.

36.

Transmission of acute gastroenteritis and respiratory illness from children to parents.

Sacri AS, De Serres G, Quach C, Boulianne N, Valiquette L, Skowronski DM.

Pediatr Infect Dis J. 2014 Jun;33(6):583-8. doi: 10.1097/INF.0000000000000220.

PMID:
24476955
37.

Randomized controlled ferret study to assess the direct impact of 2008-09 trivalent inactivated influenza vaccine on A(H1N1)pdm09 disease risk.

Skowronski DM, Hamelin ME, De Serres G, Janjua NZ, Li G, Sabaiduc S, Bouhy X, Couture C, Leung A, Kobasa D, Embury-Hyatt C, de Bruin E, Balshaw R, Lavigne S, Petric M, Koopmans M, Boivin G.

PLoS One. 2014 Jan 27;9(1):e86555. doi: 10.1371/journal.pone.0086555. eCollection 2014.

38.

Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine.

Skowronski DM, Janjua NZ, Sabaiduc S, De Serres G, Winter AL, Gubbay JB, Dickinson JA, Fonseca K, Charest H, Bastien N, Li Y, Kwindt TL, Mahmud SM, Van Caeseele P, Krajden M, Petric M.

J Infect Dis. 2014 Jul 1;210(1):126-37. Epub 2014 Jan 19.

PMID:
24446529
39.

Measles in children vaccinated with 2 doses of MMR.

Defay F, De Serres G, Skowronski DM, Boulianne N, Ouakki M, Landry M, Brousseau N, Ward BJ.

Pediatrics. 2013 Nov;132(5):e1126-33. doi: 10.1542/peds.2012-3975. Epub 2013 Oct 21.

40.

Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine.

Rouleau I, De Serres G, Drolet JP, Skowronski DM, Ouakki M, Toth E, Landry M, Ménard S, Gagnon R.

Vaccine. 2013 Dec 5;31(50):5989-96. doi: 10.1016/j.vaccine.2013.10.033. Epub 2013 Oct 19.

PMID:
24144473
41.
42.

Virus-host interactions and the unusual age and sex distribution of human cases of influenza A(H7N9) in China, April 2013.

Skowronski DM, Janjua NZ, Kwindt TL, De Serres G.

Euro Surveill. 2013 Apr 25;18(17):20465. No abstract available.

43.

Understanding suboptimal influenza vaccine effectiveness within the agent, host, and environment paradigm.

Skowronski DM, Janjua NZ, De Serres G.

Clin Infect Dis. 2013 Aug;57(3):476-7. doi: 10.1093/cid/cit256. Epub 2013 Apr 25. No abstract available.

PMID:
23619812
44.

Re: "effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy".

Skowronski DM, De Serres G, Janjua NZ, Hottes TS.

Am J Epidemiol. 2013 Mar 15;177(6):593-4. doi: 10.1093/aje/kwt021. Epub 2013 Feb 22. No abstract available.

PMID:
23436898
45.

Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada's sentinel surveillance network, January 2013.

Skowronski DM, Janjua NZ, De Serres G, Dickinson JA, Winter AL, Mahmud SM, Sabaiduc S, Gubbay JB, Charest H, Petric M, Fonseca K, Van Caeseele P, Kwindt TL, Krajden M, Eshaghi A, Li Y.

Euro Surveill. 2013 Jan 31;18(5). pii: 20394.

46.

Estimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries.

Van Kerkhove MD, Hirve S, Koukounari A, Mounts AW; H1N1pdm serology working group.

Influenza Other Respir Viruses. 2013 Sep;7(5):872-86. doi: 10.1111/irv.12074. Epub 2013 Jan 21. Review.

47.

H3N2v and other influenza epidemic risk based on age-specific estimates of sero-protection and contact network interactions.

Skowronski DM, Moser FS, Janjua NZ, Davoudi B, English KM, Purych D, Petric M, Pourbohloul B.

PLoS One. 2013;8(1):e54015. doi: 10.1371/journal.pone.0054015. Epub 2013 Jan 11.

48.

Largest measles epidemic in North America in a decade--Quebec, Canada, 2011: contribution of susceptibility, serendipity, and superspreading events.

De Serres G, Markowski F, Toth E, Landry M, Auger D, Mercier M, Bélanger P, Turmel B, Arruda H, Boulianne N, Ward BJ, Skowronski DM.

J Infect Dis. 2013 Mar 15;207(6):990-8. doi: 10.1093/infdis/jis923. Epub 2012 Dec 21.

PMID:
23264672
49.

Allergic symptoms after pandemic influenza vaccination rarely mediated by vaccine-specific IgE.

Rouleau I, De Serres G, Drolet JP, Banerjee D, Lemire C, Moore A, Paradis L, Alizadhefar R, Des Roches A, Chan ES, Stark D, Benoit M, Skowronski DM; Public Health Agency of Canada–Canadian Institutes for Health Research Influenza Research Network.

J Allergy Clin Immunol. 2012 Dec;130(6):1423-6. doi: 10.1016/j.jaci.2012.07.019. Epub 2012 Sep 6. No abstract available.

PMID:
22958947
50.

Community-acquired respiratory viruses and co-infection among patients of Ontario sentinel practices, April 2009 to February 2010.

Peci A, Winter AL, Gubbay JB, Skowronski DM, Balogun EI, De Lima C, Crowcroft NS, Rebbapragada A.

Influenza Other Respir Viruses. 2013 Jul;7(4):559-66. doi: 10.1111/j.1750-2659.2012.00418.x. Epub 2012 Aug 9.

Supplemental Content

Loading ...
Support Center